MedPath

Stent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative

Not Applicable
Recruiting
Conditions
Stone, Kidney
Stone Ureter
Registration Number
NCT05866081
Lead Sponsor
University of Michigan
Brief Summary

This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent.

Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission.

Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants.

The study team hypothesizes that:

* Pain interference change from pre-surgery to Day 7-10 will differ between the two treatment arms. This hypothesis will be evaluated separately in the randomized and observational cohorts.

* Unplanned healthcare utilization in the treatment arms will have different unplanned healthcare utilization ranks leading to a win proportion significantly higher or lower than 0.5 in the stent omission arm compared to the stent placement arm. This hypothesis will be evaluated separately in the randomized and observational cohorts.

Detailed Description

The coordinating center for this study is the Michigan Urological Surgery Improvement Collaborative (MUSIC), which is a physician-led Quality Improvement (QI) collaborative comprised of 44 urology practices and 260 urologists across the State of Michigan.

As sites are activated the registration will be updated.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
792
Inclusion Criteria
  • Undergoing unilateral ureteroscopy and lithotripsy for stone disease (participants may have contralateral stones, as long as these are asymptomatic and not being treated concurrently)
  • Largest stone less or equal to 10 millimeter in size as measured on abdominal x-ray, ultrasound, or computed tomography scan
  • Access to means of communication with the study team (email, text messaging, and/or telephone)
  • Adequate independent cognitive function and English language proficiency to complete study surveys
  • Written informed consent
Exclusion Criteria
  • Planned bilateral ureteroscopy
  • Indwelling ureteral stent or percutaneous nephrostomy tube preoperatively in either kidney
  • Anatomic abnormalities of the ipsilateral upper urinary tract (for example, horseshoe kidney, crossed fused ectopia, pelvic kidney, urinary diversion)
  • Anatomic or functional solitary kidney
  • Planned secondary or staged ureteroscopy
  • Planned use of ureteral access sheath
  • Pregnancy
  • Patients who use opiate medication daily for greater than 3 months to manage a painful condition

Second Stage Exclusion Criteria:

  • ureteral perforation
  • unanticipated anatomic abnormality
  • greater than expected bleeding
  • ureteral dilation greater than 12 French
  • ureteral access sheath utilized
  • failed ureteroscopy
  • no or incomplete lithotripsy performed
  • unable to complete case due to medical or anesthetic event.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Patient Reported Outcomes Measurement Information System (PROMIS®) Pain Interference (Short Form 6b) change at Postoperative Day 7-10 compared to preoperativePreoperative, Day 7-10

This survey has 6 questions that participants select from 1(not at all) to 5 (very much) for questions 1-5 related to pain interference. For question 6 participants select from 1 (Never) to 5 (Always). There are total of 6-30 points where the higher the score the more pain interference.

Number of Participants with Wins from the Hierarchical Unplanned stone treatment related healthcare utilization Composite Rank Scorewithin 30 days after ureteroscopy

Compare within each cohort each No Stent Placement patient head-to-head against each Stent Placement patient using a hierarchical composite comprised of:

* Intensive care unit (ICU) care during hospitalization

* Unplanned hospitalization

* Unplanned additional procedure related to ureteroscopy: operating room or interventional radiology procedure

* Emergency department visit

* Unplanned clinic visit and/or diagnostic testing (blood, urine testing and/or imaging)

* Number of ambulatory patient-provider interactions: phone calls / Electronic Medical Record (EMR) messages

Secondary Outcome Measures
NameTimeMethod
Number of Participants with Unplanned hospital admission within postoperative day 30within 30 days after ureteroscopy
Number of Participants with Intensive Care Unit care during unplanned hospital admission within postoperative day 30within 30 days after ureteroscopy
Number of Participants with Unplanned additional procedure related to ureteroscopy within postoperative day 30within 30 days after ureteroscopy
Number of Participants with Unplanned ambulatory urology office visit and/or diagnostic testing (urine testing and/or imaging) within postoperative day 30within 30 days after ureteroscopy
Unplanned ambulatory urology office visit and/or diagnostic testing (urine testing and/or imaging) within postoperative day 30within 30 days after ureteroscopy
Number of ambulatory patient-provider interactions: phone calls / EMR messages within postoperative day 30within 30 days after ureteroscopy
PROMIS® Pain Interference (Short Form 6b) change at postoperative 4-6 weeks compared to preoperativepreoperative, 4-6 weeks

This survey has 6 questions that participants select from 1(not at all) to 5 (very much) for questions 1-5 related to pain interference. For question 6 participants select from 1 (Never) to 5 (Always). There are total of 6-30 points where the higher the score the more pain intensity.

PROMIS® Pain Intensity (Short Form 3a) change at postoperative day 7-10 preoperativepreoperative, postoperative day 7-10

This is a 3-question survey that participants select from 1 (had no pain) to 5 (very severe) for the first 2 questions. For the third question participants select how level of pain is now 1 (no pain) to 5 (very severe). There are total of 3-15 points where the higher the score the more pain intensity.

National Institutes of Health (NIH) Lower Urinary Tract Dysfunction Research Network (LURN) Symptom Index-10 urinary symptom scores change at postoperative day 7-10 compared to preoperativepreoperative, postoperative day 7-10

The is 10-Item index that assesses participants urinary symptoms. For questions 1-8 Participants select from 0 (never)-4 every time. For questions 9 and 10 participants select from 0 (none) -3 (more than 3 times). There are total of 0-38 points where the higher the score the more pain symptoms.

International Consultation on Incontinence - Satisfaction (ICIQ-S) treatment satisfaction scores at postoperative 4-6 weeksPostoperative 4-6 weeks

Participants will complete this 14-question survey regarding satisfaction of treatment.

The ICIQ-S assesses aspects of experience, expectations, and outcomes to evaluate satisfaction after urological surgery. A scoring system has been derived that consists of two parts: a score for the evaluation of satisfaction with 'surgical outcomes' (ICIQ-S outcome score, range 0-24); and the overall satisfaction with surgery item, scored 0-10. Higher scores indicate more satisfaction.

PROMIS® Pain Intensity (Short Form 3a) change at postoperative 4-6 weeks compared to preoperativepreoperative, postoperative 4-6 weeks

This is a 3-question survey that participants select from 1 (had no pain) to 5 (very severe) for the first 2 questions. For the third question participants select how level of pain is now 1 (no pain) to 5 (very severe). There are total of 3-15 points where the higher the score the more pain interference.

National Institutes of Health (NIH) Lower Urinary Tract Dysfunction Research Network (LURN) Symptom Index-10 urinary symptom scores change at postoperative 4-6 weeks compared to preoperativepreoperative, postoperative 4-6 weeks

The is 10-Item index that assesses participants urinary symptoms. For questions 1-8 Participants select from 0 (never)-4 every time. For questions 9 and 10 participants select from 0 (none) -3 (more than 3 times). There are total of 0-38 points where the higher the score the more pain intensity.

International Consultation on Incontinence - Satisfaction (ICIQ-S) treatment satisfaction scores at postoperative day 7-10Postoperative day 7-10

Participants will complete this 14-question survey regarding satisfaction of treatment.

The ICIQ-S assesses aspects of experience, expectations, and outcomes to evaluate satisfaction after urological surgery. A scoring system has been derived that consists of two parts: a score for the evaluation of satisfaction with 'surgical outcomes' (ICIQ-S outcome score, range 0-24); and the overall satisfaction with surgery item, scored 0-10. Higher scores indicate more satisfaction.

Number of days taken off work by patients and caregivers during the first 7 days after ureteroscopyFirst 7 days after ureteroscopy

Trial Locations

Locations (13)

UF Health Shands Hospital

🇺🇸

Gainesville, Florida, United States

Cadillac Munson Hospital

🇺🇸

Cadillac, Michigan, United States

St. Joseph Health System Chelsea Hospital

🇺🇸

Chelsea, Michigan, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Corewell Health Buttersworth Hospital

🇺🇸

Grand Rapids, Michigan, United States

E.W Sparrow Hospital

🇺🇸

Lansing, Michigan, United States

MyMichigan Medical Center Midland

🇺🇸

Midland, Michigan, United States

Michigan Institute of Urology Town Center Ambulatory Surgery Center

🇺🇸

Troy, Michigan, United States

Monte Fiore

🇺🇸

Brooklyn, New York, United States

Mount Sinai

🇺🇸

New York, New York, United States

Scroll for more (3 remaining)
UF Health Shands Hospital
🇺🇸Gainesville, Florida, United States
Elaina Shoemaker
Contact
7347643916
esekulos@med.umich.edu
John DiBianco, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.